Disease · MONDO_0018907

craniopharyngioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. craniopharyngioma. Diseases, record MONDO_0018907. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018907

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: craniopharyngioma; Open Targets
Open Targets ID: MONDO_0018907; Open Targets
Other names: Rathke pouch neoplasm, Rathke pouch tumor, Rathke pouch tumour, Rathke's pouch neoplasm, Rathke's pouch tumor, Rathke's pouch tumour, craniopharyngioma (WHO grade I), craniopharyngioma (morphologic abnormality), craniopharyngioma, benign, cystoma, neoplasm of Rathke's pouch, tumor of Rathke's pouch, tumour of Rathke's pouch; Open Targets
Disease Ontology: DOID:3840; Disease Ontology
MeSH: D003397; MeSH
NCI Thesaurus: C2964; NCI Thesaurus
Orphanet: ORPHA:54595; Orphanet
Highest stage of its drugs: Phase 2, for 6 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
COBIMETINIB	CHEMBL2146883	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUDEOXYGLUCOSE F 18	CHEMBL2030434	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
METHIONINE	CHEMBL42336	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PEGINTERFERON ALFA-2B	CHEMBL1201561	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TOVORAFENIB	CHEMBL3348923	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VEMURAFENIB	CHEMBL1229517	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CATEQUENTINIB	CHEMBL4303201	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets11

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
BRAF	RAF serine/threonine protein kinase	2	RAF serine/threonine protein kinase inhibitor; Serine/threonine-protein kinase B-raf inhibitor	Phase 2	https://conductscience.org/library/genes/673	Drugs and targets
ARAF	RAF serine/threonine protein kinase	1	RAF serine/threonine protein kinase inhibitor	Phase 2	https://conductscience.org/library/genes/369	Drugs and targets
FLT4	Vascular endothelial growth factor receptor 3	1	Vascular endothelial growth factor receptor 3 inhibitor	Phase 1/2	https://conductscience.org/library/genes/2324	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	1	Interferon alpha/beta receptor agonist	Phase 2	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	1	Interferon alpha/beta receptor agonist	Phase 2	https://conductscience.org/library/genes/3455	Drugs and targets
KDR	Vascular endothelial growth factor receptor 2	1	Vascular endothelial growth factor receptor 2 inhibitor	Phase 1/2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3815	Drugs and targets
MAP2K1	Dual specificity mitogen-activated protein kinase kinase 1	1	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5604	Drugs and targets
MAP2K2	Dual specificity mitogen-activated protein kinase kinase 2	1	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor	Phase 2	https://conductscience.org/library/genes/5605	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor beta	1	Platelet-derived growth factor receptor beta inhibitor	Phase 1/2	https://conductscience.org/library/genes/5159	Drugs and targets

1 to 10 of 11

See all 11 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01964300	Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery	Phase 2	19	2020-02-24	Childhood Craniopharyngioma	PEGINTERFERON ALFA-2B	Its record names the disease	ClinicalTrials.gov
NCT01419067	A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection	Phase 2	112		Craniopharyngioma	METHIONINE	Its record names the disease	ClinicalTrials.gov
NCT05465174	Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults	Phase 2	57		Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma	TOVORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT06970145	Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma	Phase 1/2	57		Craniopharyngiomas	CATEQUENTINIB	Its record names the disease	ClinicalTrials.gov
NCT03224767	Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma	Phase 2	24		BRAF V600E Mutation Present, Papillary Craniopharyngioma	COBIMETINIB, VEMURAFENIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Stratum 1 vs Stratum 2: deaths from any cause	0 of 7	1 of 12	19	NCT01964300	Trial comparisons
Stratum 1 vs Stratum 2: serious adverse events	1 of 7	5 of 12	19	NCT01964300	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42083012	DERIVED	1	PubMed
37437144	DERIVED	1	PubMed
37084748	DERIVED	1	PubMed
33607632	DERIVED	1	PubMed
32086697	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018907

GET https://conductscience.org/api/diseases/v1/MONDO_0018907/drugs

API reference For AI assistants